Zydus Lifesciences receives 6 observations from USFDA for Gujarat API unit
[ad_1] Zydus Lifesciences on Saturday said it received six observations from the US Food and Drug Administration (USFDA) following a surveillance inspection of its active pharmaceutical ingredient (API) manufacturing facility in Dabhasa, Gujarat.In a regulatory filing, the company stated that the inspection was conducted between April 21 and April 25, 2025.“We wish to inform that…